Quotes 5-day view Delayed Nasdaq
01/14/2021
01/15/2021
01/19/2021
01/20/2021
01/21/2021
Date
92.04(c)
90.56(c)
93.96(c)
96.37(c)
93.9(c)
Last
1 143 434
930 173
995 950
937 022
1 175 144
Volume
-0.75%
-1.61%
+3.75%
+2.56%
-2.56%
Change
Sales 2020
2 530 M
-
-
Net income 2020
-334 M
-
-
Net cash position 2020
1 843 M
-
-
P/E ratio 2020
-62,0x
Yield 2020
-
Sales 2021
2 868 M
-
-
Net income 2021
576 M
-
-
Net cash position 2021
2 490 M
-
-
P/E ratio 2021
36,0x
Yield 2021
-
Capitalization
20 564 M
20 564 M
-
EV / Sales 2020
7,40x
EV / Sales 2021
6,30x
Nbr of Employees
1 456
Free-Float
98,6%
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (82.2%);
- royalties (14.2%);
- income from research and cooperation agreements (3.6%).
Notations Surperformance© of Incyte Corporation
Trading Rating :
Investor Rating :
All news about INCYTE CORPORATION
News in other languages on INCYTE CORPORATION
Analyst Recommendations on INCYTE CORPORATION
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends INCYTE CORPORATION
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
20
Average target price
107,06 $
Last Close Price
93,90 $
Spread / Highest target
41,6%
Spread / Average Target
14,0%
Spread / Lowest Target
-5,22%
Please enable JavaScript in your browser's settings to use dynamic charts.